Oncology
1 drug is in development for Diffuse Large B-Cell Lymphoma.
- Companies
- 1
- Clinical trials
- 20
Prepared research question
Which programs lead the Diffuse Large B-Cell Lymphoma pipeline—and what evidence could change the picture?
Traceable citations · Unknowns marked
Drug Pipeline by Phase
| Drug | Company |
|---|---|
| ezm0414 | Epizyme, Inc. (EPZM) |
About this indication
Diffuse Large B-Cell Lymphoma context
Also known as: Diffuse Histiocytic Lymphoma, Diffuse Histiocytic Lymphomas, Diffuse Large Cell Lymphoma, Diffuse Large-Cell Lymphomas, Histiocytic Lymphoma, Histiocytic Lymphomas, Large Lymphoid Lymphoma, Diffuse, Lymphoma, Histiocytic, Diffuse, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large Cell, Diffuse, Lymphoma, Large Lymphoid, Diffuse
Prevalence
10.0 / 100K
Incidence
5.6 / 100K/yr
Frequently asked questions
How many drugs are in development for Diffuse Large B-Cell Lymphoma?
BioSniper tracks 1 drug in development for Diffuse Large B-Cell Lymphoma across 1 company.
How many clinical trials target Diffuse Large B-Cell Lymphoma?
There are 20 clinical trials targeting Diffuse Large B-Cell Lymphoma tracked by BioSniper.
What is the prevalence of Diffuse Large B-Cell Lymphoma?
The estimated prevalence of Diffuse Large B-Cell Lymphoma is approximately 10.0 per 100,000 population.